Ginkgo Biloba: The Definitive Guide

What is ginkgo biloba?

Ginkgo biloba is a tree whose leaf is used in oral extracts. Clinical research generally concerns standardized leaf extracts, especially EGb 761, rather than raw leaf tea, seeds, nuts, root or an unnamed powder. Fresh seeds are toxic, and serious effects have occurred with roasted seeds or crude plant material. [1], [5]

Ginkgo is marketed for memory, dementia, circulation, tinnitus and “brain health.” The evidence does not support one broad conclusion. Large prevention trials were negative. A 2026 Cochrane review found little or no benefit for mild cognitive impairment at six months, while some dementia scales showed uncertain small-to-moderate signals. [2], [3], [4]

Product identity matters. A standardized extract amount, its leaf equivalent, flavonoid glycosides, terpene lactones and ginkgolic-acid limit should all be visible before a study can be compared with a bottle. [1]

Typical Ginkgo Biloba Protocols

There is no RDA, AI or established UL for ginkgo. The monograph's licensing range does not override its duration limits, contraindications or the null prevention evidence.

Titration

No evidence-based self-titration is established. The Canadian dose bands control label duration language rather than define escalation steps.

Timing

GEM and GuidAge used twice-daily schedules. Evidence does not show that fasted, meal, morning or evening timing changes cognitive outcomes.

Duration

Prevention trials lasted years and were null. Shorter treatment findings remain population- and scale-specific; longer exposure does not turn prevention evidence positive.

Stopping

No taper is established. Stop and seek review for unusual bleeding, seizure, severe allergy or a new neurologic symptom; disclose use before surgery.

What is ginkgo commonly used for?

Common uses include memory, attention, dementia prevention, dementia symptoms, tinnitus, circulation, anxiety and vertigo. NCCIH concludes there is no conclusive evidence for any health condition and specifically finds no demonstrated benefit for preventing or slowing dementia. It also says healthy-person cognitive performance remains uncertain. [5]

For diagnosed dementia, the 2026 Cochrane review found low-certainty small-to-moderate signals at six months on some global, cognitive and daily-function scales, but high heterogeneity. For MCI, moderate-certainty evidence indicated little or no effect at six months on global status, cognition or instrumental daily activities. [2]

Which form and label details matter?

Read the label in this order:

1. Part: leaf extract, not seed, nut, root or crude plant.
2. Extract identity: EGb 761 or another clearly specified extract; do not infer equivalence from the species alone.
3. Standardization: 22–27% flavonoid glycosides and 5–7% terpene lactones for the current Canadian pathway. [1]
4. Ginkgolic acids: finished product no more than 5 ppm under the Canadian monograph. [1]
5. Actual extract and leaf equivalent: milligrams of extract are not grams of dried leaf.
6. Lot and quality testing: identity, marker assay, ginkgolic acids, microbes, heavy metals and adulterants.

Raw ginkgo seeds and crude plant material should not be substituted for standardized leaf extract. “24/6,” “brain support” and “clinically studied” do not identify the exact trial product by themselves.

What does the human evidence show?

Dementia prevention

GEM randomized 3,069 community-dwelling adults aged 75 or older to 120 mg standardized extract twice daily or placebo and followed them for a median 6.1 years. Dementia occurred in 277 ginkgo participants and 246 placebo participants. Ginkgo did not reduce all-cause dementia (HR 1.12, 95% CI 0.94–1.33), Alzheimer disease or progression from MCI. [3]

GuidAge enrolled 2,854 adults aged 70 or older with memory complaints. Among those who took at least one dose, 1,406 received ginkgo and 1,414 placebo. After five years, probable Alzheimer disease occurred in 61 versus 73 participants (HR 0.84, 95% CI 0.60–1.18; p=0.306), a nonsignificant result. [4]

Together, these trials do not support ginkgo for dementia prevention.

Cognitive impairment and dementia symptoms

The 2026 Cochrane review separated cognitive complaints, MCI, multiple-sclerosis-related cognitive impairment and dementia. At six months in MCI, ginkgo probably had little or no effect on global clinical status, cognition or instrumental activities of daily living. [2]

In dementia, low-certainty evidence suggested small-to-moderate improvements on some global, cognitive and daily-activity scales, with substantial heterogeneity. Other measures at six months showed little or no difference with moderate certainty. These findings do not prove disease modification, cure or prevention, and they cannot be generalized to a healthy person seeking sharper memory. [2]

How might it work?

Ginkgo leaf extracts contain flavonoid glycosides and terpene lactones. Proposed laboratory actions include antioxidant effects, platelet-activating-factor antagonism, vascular effects and changes in neuronal signaling. These hypotheses vary by extract and exposure. [1], [5]

Mechanistic plausibility cannot rescue a null prevention result. It also does not show that a consumer product improves memory or define a dose.

What are the risks and interactions?

Commonly reported effects include dizziness, headache and gastrointestinal symptoms. Allergic skin reactions and more severe allergy can occur. Fresh seeds are toxic, and crude or roasted seed exposures are unsafe. [5]

Ginkgo may increase bleeding risk with warfarin and other anticoagulant or antiplatelet medicines. Health Canada's monograph says not to use it with blood thinners, other products that affect coagulation, or when having surgery. It requires professional advice with seizure, diabetes or high-blood-pressure medicines. [1], [5]

Health Canada reported 15 domestic suspected arrhythmia reports through June 30, 2020, including 10 serious reports, but the information was insufficient to assess causation. This is a signal for vigilance, not an incidence estimate or proof. [6]

Canada's January 2025 public page also describes a draft chemical assessment proposing potential risks, including liver cancer and developmental effects, and advises limiting exposure while the assessment remains unfinished. This is a proposed hazard and risk-management process, not a final conclusion about ordinary clinical use. [7]

Pregnancy may carry early-labor or bleeding concerns, and breastfeeding evidence is sparse. Seizure history, bleeding disorders and planned procedures require clinician review. These cautions apply in the United States and Canada; legal sale does not prove benefit or compatibility with medicines.

Seek urgent care for uncontrolled bleeding, black or bloody stool, sudden severe headache, one-sided weakness, seizure, fainting, chest symptoms, severe palpitations or facial or throat swelling.

Legal status in the United States and Canada

In the United States, ginkgo leaf extracts are sold as dietary supplements and do not receive FDA premarket approval for effectiveness. [5]

In Canada, licensed natural health products carry an NPN. The July 2025 monograph specifies leaf material, extract standardization, dose and duration bands, contraindications and a ginkgolic-acid limit. [1]

What should you monitor?

Record extract identity, standardization, ginkgolic-acid specification, leaf equivalent, amount, frequency, start date, medicines and planned procedures. Track dizziness, headache, digestive symptoms, bruising, bleeding, palpitations or seizure symptoms.

Memory concerns warrant clinical assessment because sleep disorders, depression, medicines, thyroid disease, hearing loss and neurologic disease can look similar. A daily rating cannot diagnose dementia or show that ginkgo prevents it.

What happens when you stop?

No withdrawal syndrome or taper is established. Stop before a procedure according to the surgical team's instructions, and seek assessment rather than restarting after unexplained bleeding, seizure or a new neurologic event.

How should it be stored?

Follow the label. Keep extracts closed, dry, away from heat and out of reach of children and pets. Do not store or consume home-prepared seeds as a substitute for leaf extract.

How does ginkgo compare with other approaches?

Evaluation of reversible causes, hearing support, physical activity, vascular-risk management and evidence-based dementia care address outcomes that ginkgo cannot be assumed to improve. Ginkgo did not prevent dementia in large trials.

Bacopa, lion's mane, huperzine A and prescription cognitive medicines have different interventions, evidence and risks. Results cannot be transferred across them or combined into an evidence-based “nootropic stack.”

What do public communities add?

Public discussions can reveal headaches, digestive effects, label confusion and use alongside medicines. They cannot diagnose cognitive change, detect bleeding risk or prove sharper memory. Subjective “clarity” is vulnerable to expectation, sleep and concurrent caffeine or medicine changes.

Common questions

Does ginkgo prevent dementia or Alzheimer disease?

No. GEM and GuidAge did not show a significant preventive effect. [3], [4]

Does ginkgo treat dementia?

The 2026 Cochrane review found low-certainty signals on some dementia symptom scales and little or no difference on others. That is not cure or disease modification. [2]

Does ginkgo improve memory in healthy adults?

It remains uncertain. NCCIH says healthy-person cognitive evidence is largely low quality. [5]

Is EGb 761 the same as any 24/6 extract?

No. Similar marker percentages do not guarantee identical manufacturing, constituents, ginkgolic acids or clinical equivalence.

Can ginkgo be taken with warfarin or aspirin?

Do not self-combine it with blood thinners or other products affecting coagulation. Review anticoagulants and antiplatelet medicines with the prescriber. [1], [5]

Should ginkgo be stopped before surgery?

Yes, Health Canada's monograph contraindicates use when having surgery. The surgical team should set the stop interval. [1]

Are ginkgo seeds or tea equivalent to leaf extract?

No. Fresh seeds are toxic, serious effects have occurred with roasted seeds or crude plant, and clinical studies use defined leaf extracts. [5]

Is ginkgo safe during pregnancy or breastfeeding?

Pregnancy may carry labor or bleeding concerns, and breastfeeding evidence is inadequate. Avoid self-directed use. [1], [5]

Glossary

Terms used in this guide.

EGb 761

A specific standardized ginkgo leaf extract used in many trials; it is not a generic name for all ginkgo products.

Mild cognitive impairment

Measurable cognitive change greater than expected for age that does not necessarily meet dementia criteria.

Ginkgolic acids

Potentially toxic and allergenic constituents restricted to no more than 5 ppm in products following the Canadian monograph.

Flavonoid glycosides

A constituent class used to standardize some ginkgo leaf extracts.

Terpene lactones

A ginkgo constituent class that includes ginkgolides and bilobalide and appears in extract specifications.

Hazard ratio

A comparison of event rates over time; a confidence interval crossing 1 does not show a statistically significant difference.

Titration

Changing an amount in planned steps. No general ginkgo self-titration is established.

How this guide was researched

This draft used Health Canada's July 2025 ginkgo monograph and current public risk pages, NCCIH's February 2025 clinical summary, the February 2026 Cochrane review, GEM and GuidAge prevention trials, and Health Canada's arrhythmia signal notice. Searches covered extract identity, cognition, dementia prevention, MCI, treatment scales, bleeding, seizures, arrhythmia, pregnancy and regulation.

Corrections to the legacy manuscript include leading with the large null prevention trials; separating prevention, MCI and dementia symptom questions; replacing broad “brain blood flow” and healthy-memory claims with outcome-specific evidence; restoring Canadian duration bands and ginkgolic-acid limits; and removing unsupported stacking, cycling and best-time claims. Evidence was refreshed October 9, 2026.

How this guide was made

The source ledger stores extract identity, population, schedule, outcome, access level, funding and limitations. Primary trials support prevention rows; official and systematic-review sources frame current certainty and risks. Draft status means scientific, French-parity, asset and rendered-page review remain separate gates.

Sources

Related guides